Literature DB >> 23806261

Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself.

Stina Dinsen1, Bo Baslund, Marianne Klose, Aase Krogh Rasmussen, Lennart Friis-Hansen, Linda Hilsted, Ulla Feldt-Rasmussen.   

Abstract

Glucocorticoid therapy is widely used, but withdrawal from glucocorticoids comes with a potential life-threatening risk of adrenal insufficiency. Recent case reports document that adrenal crisis after glucocorticoid withdrawal remains a serious problem in clinical practice. Partly due to difficulties in inter-study comparison the true prevalence of glucocorticoid-induced adrenal insufficiency is unknown, but it might be somewhere between 46 and 100% 24h after glucocorticoid withdrawal, 26-49% after approximately one week, and some patients show prolonged suppression lasting months to years. Adrenal insufficiency might therefore be underdiagnosed in clinical practice. Clinical data do not permit accurate estimates of a lower limit of glucocorticoid dose and duration of treatment, where adrenal insufficiency will not occur. Due to individual variation, neither the glucocorticoid dose nor the duration of treatment can be used reliably to predict adrenal function after glucocorticoid withdrawal. Also the recovery rate of the adrenal glands shows individual variation, which may be why there is currently insufficient evidence to prove the efficacy and safety of different withdrawal regimens. Whether a patient with an insufficient response to an adrenal stimulating test develops clinically significant adrenal insufficiency depends on the presence of stress and resulting glucocorticoid demand and it is thus totally unpredictable and can change relative fast. Adrenal insufficiency should therefore always be taken seriously. Individual variation in hypothalamic-pituitary-adrenal axis function might be due to differences in glucocorticoid sensitivity and might be genetic. Further awareness of the potential side effect of withdrawal of glucocorticoid and further research are urgently needed.
Copyright © 2013 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adrenal insufficiency; Glucocorticoid withdrawal; Glucocorticoid-induced adrenal insufficiency; Glucocorticoids

Mesh:

Substances:

Year:  2013        PMID: 23806261     DOI: 10.1016/j.ejim.2013.05.014

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  32 in total

1.  Factors associated with multiple recurrences of nonspecific orbital inflammation aka orbital pseudotumor.

Authors:  Puneet S Braich; Robin K Kuriakose; Naveen S Khokhar; Jared C Donaldson; Timothy J McCulley
Journal:  Int Ophthalmol       Date:  2017-06-20       Impact factor: 2.031

2.  Dexamethasone-related adrenal insufficiency in patients with brain and skull base tumours.

Authors:  H Benghiat; P Sanghera; D Stange; P Nightingale; A Hartley; M W O'Reilly; N Nundall; H Currie; M Ali; G Cruickshank; D Spooner; A Toogood
Journal:  Support Care Cancer       Date:  2018-06-01       Impact factor: 3.603

Review 3.  The unresolved riddle of glucocorticoid withdrawal.

Authors:  F Guerrero Pérez; A P Marengo; C Villabona Artero
Journal:  J Endocrinol Invest       Date:  2017-05-20       Impact factor: 4.256

Review 4.  Adrenal cortical insufficiency--a life threatening illness with multiple etiologies.

Authors:  Marcus Quinkler; Felix Beuschlein; Stefanie Hahner; Gesine Meyer; Christof Schöfl; Günter K Stalla
Journal:  Dtsch Arztebl Int       Date:  2013-12-23       Impact factor: 5.594

Review 5.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

6.  Global and Targeted Metabolomics Evidence of the Protective Effect of Chinese Patent Medicine Jinkui Shenqi Pill on Adrenal Insufficiency after Acute Glucocorticoid Withdrawal in Rats.

Authors:  Linjing Zhao; Aihua Zhao; Tianlu Chen; Wenlian Chen; Jiajian Liu; Runmin Wei; Jing Su; Xuelan Tang; Keyi Liu; Ran Zhang; Guoxiang Xie; Jun Panee; Mingfeng Qiu; Wei Jia
Journal:  J Proteome Res       Date:  2016-06-20       Impact factor: 4.466

7.  Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.

Authors:  Le Min; Frank Stephen Hodi; Anita Giobbie-Hurder; Patrick A Ott; Jason J Luke; Hilary Donahue; Meredith Davis; Rona S Carroll; Ursula B Kaiser
Journal:  Clin Cancer Res       Date:  2014-12-23       Impact factor: 12.531

8.  Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis.

Authors:  Michele Iudici; Serena Vettori; Barbara Russo; Veronica Giacco; Domenico Capocotta; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2016-05-17       Impact factor: 2.980

9.  Methylprednisolone Pulse Treatment of Graves' Ophthalmopathy Is Not Associated with Secondary Adrenocortical Insufficiency.

Authors:  Sofie Jespersen; Birte Nygaard; Lars Østergaard Kristensen
Journal:  Eur Thyroid J       Date:  2015-10-27

10.  Screening practices for paediatric asymptomatic adrenal suppression in Canada: Are we addressing this important risk?

Authors:  Ellen B Goldbloom; Alexandra Ahmet
Journal:  Paediatr Child Health       Date:  2019-03-30       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.